PROVECTUS BIOPHARMACEUTICALS, INC. (DE)
PVCT
PVCT was delisted on the 13th of October, 2016.
45 hedge funds and large institutions have $3.13M invested in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in 2016 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 13 increasing their positions, 7 reducing their positions, and 3 closing their positions.
86% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 7
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
2% more funds holding
Funds holding: 44 → 45 (+1)
1% more capital invested
Capital invested by funds: $3.1M → $3.13M (+$27.7K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$33.1K |
| 2 |
Goldman Sachs
New York
|
+$23K |
| 3 |
Stifel Financial
St. Louis,
Missouri
|
+$13.3K |
| 4 |
Renaissance Technologies
New York
|
+$12.3K |
| 5 |
HNB
Huntington National Bank
Columbus,
Ohio
|
+$10.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$241K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$31.8K |
| 3 |
LPL Financial
San Diego,
California
|
-$22.5K |
| 4 |
Millennium Management
New York
|
-$15K |
| 5 |
AIG
American International Group
New York
|
-$9K |
PVCT Hedge Fund Activity: Q2 2016 in Review
45 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) for Q2 2016, worth a combined $3.13M — up 0.89% from $3.1M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new PVCT positions and 3 closed out — a net gain of 1 holder — while 13 added to existing stakes and 7 trimmed.
The largest buyer was UBS Group, adding an estimated $33.1K. The largest seller was Sabby Management, cutting an estimated $241K.
- 45 institutional investors held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) as of Q2 2016, up from 44 in Q1 2016.
- Funds reported $3.13M of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) stock for Q2 2016, up 0.89% quarter-over-quarter.
- 4 funds opened new PROVECTUS BIOPHARMACEUTICALS, INC. (DE) positions in Q2 2016 and 3 closed out, a net change of +1 holder.
- The largest PROVECTUS BIOPHARMACEUTICALS, INC. (DE) buyer in Q2 2016 was UBS Group, an estimated $33.1K added.
- The largest PROVECTUS BIOPHARMACEUTICALS, INC. (DE) seller in Q2 2016 was Sabby Management, an estimated $241K sold.
Based on aggregated 13F filings for Q2 2016.